Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.49 |
| ▸ | MMP13 | P45452 | 12/20 | 0.47 |
| ▸ | MMP2 | P08253 | 11/20 | 0.47 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | TARS1 | P26639 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 4/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504669 | 0.77 | SLC1A2 (0.47) | MMP2ADAMTS4CA2CA9 | |
| SCHEMBL3718689 | 0.77 | MMP2 (0.53) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL569560 | 0.74 | MMP2 (0.52) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL3710102 | 0.74 | MMP13 (0.54) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL9891445 | 0.71 | PDK1 (0.47) | LTA4H | |
| SCHEMBL7354064 | 0.70 | MMP9 (0.69) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL28761685 | 0.70 | SLC1A3 (0.55) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL1798546 | 0.69 | MMP9 (0.67) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL1798547 | 0.69 | MMP9 (0.67) | MMP9MMP13MMP2MMP3ADAMTS4 | |
| SCHEMBL569559 | 0.69 | CA1 (0.65) | MMP13MMP2ADAMTS4MMP1MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993544-B2 | Carbamoylphosphonates as inhibitors and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| EP-2393495-B1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RES DEV CO (IL) | 2014-07-23 | — | — | EP | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | MMP9, MMP26, MMP25 | MMP9 1/4885MMP13 8/4885MMP2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.